Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 88

Sort by

Sort Order Select

Journal Articles

Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project

Blood blood.2024026186.

https://doi.org/10.1182/blood.2024026186

Published: 2024

Includes: Supplemental data

Journal Articles

Profiling Baseline Health-Related Quality of Life of Patients with Newly Diagnosed Myeloid Malignancies: A Pooled Analysis of 3349 Patients with AML, APL and MDS from the International Proactive Project

Fabio Efficace, Adriano Venditti, Thomas Baldi, Joanna Canham, Giovanni Martinelli, Alfonso Piciocchi, Mike Dennis, Steve Knapper, Nigel H. Russell, Sean Johnson, Maria Teresa Voso, Marco Vignetti, Ian Thomas

Blood (2024) 144 (Supplement 1): 407.

https://doi.org/10.1182/blood-2024-204588

Published: 2024

Journal Articles

Identification of Genomic Structural Variants (SVs) with Adverse Prognostic Significance in Normal-Karyotype (nk) Acute Myeloid Leukemia (AML) Patients

Blood (2024) 144 (Supplement 1): 65.

https://doi.org/10.1182/blood-2024-198342

Published: 2024

Journal Articles

Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820

Blood (2024) 144 (Supplement 1): 835.

https://doi.org/10.1182/blood-2024-207892

Published: 2024

Journal Articles

ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial

Blood (2024) 144 (Supplement 1): 3158.

https://doi.org/10.1182/blood-2024-205465

Published: 2024

Journal Articles

Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network

Blood (2024) 144 (Supplement 1): 992.

https://doi.org/10.1182/blood-2024-210201

Published: 2024

Journal Articles

Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia

Alfonso Piciocchi, Monica Messina, Giovanni Marsili, Marta Cipriani, Francesca Paola Paoloni, Davide Lazzarotto, Anna Candoni, Alessandro Rambaldi, Matteo Leoncin, Paola Fazi, Marco Vignetti, Robin Foà, Sabina Chiaretti

Blood (2024) 144 (Supplement 1): 274.

https://doi.org/10.1182/blood-2024-200643

Published: 2024

Journal Articles

Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study

Alfonso Piciocchi, Giovanni Marsili, Ylenia Belperio, Monica Messina, Francesca Paola Paoloni, Stefano Soddu, Isabella Capodanno, Rosaria Sancetta, Elisabetta Abruzzese, Alessandro Pulsoni, Monia Lunghi, Giovanni Caocci, Fausto Castagnetti, Paola Fazi, Marco Vignetti, Massimo Breccia, Fabrizio Pane

Blood (2024) 144 (Supplement 1): 4530.

https://doi.org/10.1182/blood-2024-198366

Published: 2024

Journal Articles

Long-Term Safety and Effectiveness of Ponatinib Treatment in Patients with TKI Intolerance: Subgroup Analysis of the Observational Study of Ponatinib Treatment in Patients with CML in Italy (OITI)

Massimo Breccia, Alessandra Iurlo, Fabrizio Pane, Anna Rita Scortechini, Immacolata Attolico, Marco Santoro, Marco Cerrano, Francesca Lunghi, Alessandro Maggi, Nicola Di Renzo, Valeria Sargentini, Alfonso Piciocchi, Claudia Tringali, Alessandra Malato

Blood (2024) 144 (Supplement 1): 2427.

https://doi.org/10.1182/blood-2024-200389

Published: 2024

Journal Articles

Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Italy: Preliminary Results of the Observational Study By the Gimema Working Party on Chronic Lymphoproliferative Disorders and By the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 1872.

https://doi.org/10.1182/blood-2024-199014

Published: 2024

Journal Articles

Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML

Blood (2024) 144 (Supplement 1): 1574.

https://doi.org/10.1182/blood-2024-198139

Published: 2024

Journal Articles

Venetoclax and Azacitidine for Relapse Prevention in NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial

Blood (2024) 144 (Supplement 1): 2893.

https://doi.org/10.1182/blood-2024-210315

Published: 2024

Journal Articles

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2024-207842

Published: 2024

Journal Articles

Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome

Blood (2024) 144 (Supplement 1): 2690.

https://doi.org/10.1182/blood-2024-194413

Published: 2024

Journal Articles

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Blood (2023) 142 (Supplement 1): 6544.

https://doi.org/10.1182/blood-2023-188454

Published: 2023

Journal Articles

Autologous STEM Cell Collection after Daratumumab, Bortezomib, Thalidomide and Dexamethasone Versus Bortezomib, Thalidomide and Dexamethasone in NEWLY Diagnosed Multiple Myeloma: A Real-Life Monocentric Italian Experience

Francesca Fazio, Mauro Passucci, Jacopo Micozzi, Silvia Sorella, Chiara Lisi, David Fanciullo, Alfonso Piciocchi, Mahnaz Shafii Bafti, Maurizio Martelli, Maria Gozzer, Maria Teresa Petrucci

Blood (2023) 142 (Supplement 1): 6651.

https://doi.org/10.1182/blood-2023-188780

Published: 2023

Journal Articles

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

Blood (2023) 142 (Supplement 1): 826.

https://doi.org/10.1182/blood-2023-174973

Published: 2023

Journal Articles

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Blood (2023) 142 (Supplement 1): 3178.

https://doi.org/10.1182/blood-2023-188305

Published: 2023

Journal Articles

Long-Term Outcome of 1296 Patients with Newly Diagnosed with APL: A Harmony Alliance Study

Luca Guarnera, Soren Lehmann, Konstanze Döhner, Hartmut Döhner, Uwe Platzbecker, Nigel H. Russell, Richard Dillon, Ian Thomas, Gert Ossenkoppele, Marco Vignetti, Edoardo la Sala, Alfonso Piciocchi, Angela Villaverde Ramiro, Laura Tur, Carmelo Gurnari, Lars Bullinger, Jesús María Hernández-Rivas, Maria Teresa Voso

Blood (2023) 142 (Supplement 1): 727.

https://doi.org/10.1182/blood-2023-185121

Published: 2023

Journal Articles

LONG-TERM Results of the Frontline Dasatinib/Blinatumomabprotocol (D-ALBA, GIMEMA LAL2116) for Adult Ph+ Acutelymphoblastic Leukemia

Robin Foà, Renato Bassan, Loredana Elia, Alfonso Piciocchi, Stefano Soddu, Monica Messina, Felicetto Ferrara, Monia Lunghi, Antonino Mulè, Massimiliano Bonifacio, Nicola Fracchiolla, Prassede Salutari, Paola Fazi, Anna Guarini, Alessandro Rambaldi, Sabina Chiaretti

Blood (2023) 142 (Supplement 1): 4250.

https://doi.org/10.1182/blood-2023-187773

Published: 2023

NARROW

Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project

Profiling Baseline Health-Related Quality of Life of Patients with Newly Diagnosed Myeloid Malignancies: A Pooled Analysis of 3349 Patients with AML, APL and MDS from the International Proactive Project

Identification of Genomic Structural Variants (SVs) with Adverse Prognostic Significance in Normal-Karyotype (nk) Acute Myeloid Leukemia (AML) Patients

Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820

Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network

Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia

Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study

Long-Term Safety and Effectiveness of Ponatinib Treatment in Patients with TKI Intolerance: Subgroup Analysis of the Observational Study of Ponatinib Treatment in Patients with CML in Italy (OITI)

Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML

Venetoclax and Azacitidine for Relapse Prevention in NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Autologous STEM Cell Collection after Daratumumab, Bortezomib, Thalidomide and Dexamethasone Versus Bortezomib, Thalidomide and Dexamethasone in NEWLY Diagnosed Multiple Myeloma: A Real-Life Monocentric Italian Experience

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Long-Term Outcome of 1296 Patients with Newly Diagnosed with APL: A Harmony Alliance Study

LONG-TERM Results of the Frontline Dasatinib/Blinatumomabprotocol (D-ALBA, GIMEMA LAL2116) for Adult Ph+ Acutelymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only